🟢 Moleculin Biotech is trading 6.17% up in pre-market after positive interim MIRACLE trial results

Moleculin Biotech is trading 6.17% up now at $0.65 after its August 14, 2026 earnings release highlighted positive interim MIRACLE trial results and continued progress toward a potential 2027 NDA filing.

• Reported a $7.6 million quarterly loss but secured $9.3 million in post-quarter financing, extending its expected cash runway into early 2027.
• Shares have risen for six consecutive sessions, from $0.39 to $0.61 by August 14.